Based on the Viridian Therapeutics Inc stock forecast from 9 analysts, the average analyst target price for Viridian Therapeutics Inc is USD 39.13 over the next 12 months. Viridian Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Viridian Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Viridian Therapeutics Inc’s stock price was USD 13.13. Viridian Therapeutics Inc’s stock price has changed by -1.28% over the past week, -13.96% over the past month and -10.07% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for VRDN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
